Venus Remedies (526953) Stock Overview
Engages in the pharmaceutical business in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
526953 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Venus Remedies Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹441.25 |
| 52 Week High | ₹565.95 |
| 52 Week Low | ₹272.20 |
| Beta | 0.40 |
| 1 Month Change | -6.52% |
| 3 Month Change | 2.71% |
| 1 Year Change | 26.13% |
| 3 Year Change | 98.72% |
| 5 Year Change | 204.52% |
| Change since IPO | 1,064.25% |
Recent News & Updates
Recent updates
Shareholder Returns
| 526953 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -4.3% | 1.3% | 1.6% |
| 1Y | 26.1% | -6.2% | -6.1% |
Return vs Industry: 526953 exceeded the Indian Pharmaceuticals industry which returned -6.2% over the past year.
Return vs Market: 526953 exceeded the Indian Market which returned -6.1% over the past year.
Price Volatility
| 526953 volatility | |
|---|---|
| 526953 Average Weekly Movement | 5.0% |
| Pharmaceuticals Industry Average Movement | 5.0% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in IN Market | 8.0% |
| 10% least volatile stocks in IN Market | 3.3% |
Stable Share Price: 526953 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 526953's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 1,298 | Ashutosh Jain | www.venusremedies.com |
Venus Remedies Limited engages in the pharmaceutical business in India and internationally. It is involved in the research and development of solutions focusing on antimicrobial resistance and oncology. The company also offers analgesic, analgesic and antipyretic, antibiotic, anticoagulant, antiemetic, antiviral, cardiovascular, disinfectant and antiseptic, gastro therapy, hepatoprotective, hormones (steroid), immunostimulating agent, iron supplements, muscle relaxant, neurology, oncology, and solvent products, as well as herbal medicine.
Venus Remedies Limited Fundamentals Summary
| 526953 fundamental statistics | |
|---|---|
| Market cap | ₹5.90b |
| Earnings (TTM) | ₹536.95m |
| Revenue (TTM) | ₹6.71b |
Is 526953 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 526953 income statement (TTM) | |
|---|---|
| Revenue | ₹6.71b |
| Cost of Revenue | ₹3.97b |
| Gross Profit | ₹2.75b |
| Other Expenses | ₹2.21b |
| Earnings | ₹536.95m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 40.17 |
| Gross Margin | 40.91% |
| Net Profit Margin | 8.00% |
| Debt/Equity Ratio | 0.3% |
How did 526953 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/16 18:52 |
| End of Day Share Price | 2025/09/16 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Venus Remedies Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ashish Kushwaha | FirstCall Research |
| Nagaraju Airruva | FirstCall Research |